X4 Pharmaceuticals (XFOR) Non Operating Income (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Non Operating Income came in at -$226000.0 in Q4 2025, up 94.13% YoY from -$116418.7 in Q4 2024, and up 90.33% on a QoQ basis from -$2.3 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Non Operating Income (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Non Operating Income data on file, last reported at -$226000.0 in Q4 2025.
- Quarterly Non Operating Income rose 94.13% year-over-year to -$226000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.7 million (up 1145.33% YoY) and the FY2025 annual result came in at $7.7 million, up 1145.33% from the prior year.
- Non Operating Income grew to -$226000.0 in Q4 2025, from -$2.3 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $24.9 million in Q3 2023 to a low of -$29.9 million in Q2 2023.
- A 5-year average of $178850.0 and a median of -$704000.0 in 2021 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1825.61% in 2023, down 4585.27% in 2023.
- Tracing XFOR's Non Operating Income over 5 years: stood at -$1.1 million in 2021, then sank by 205.74% to -$3.5 million in 2022, then surged by 273.7% to $6.1 million in 2023, then sank by 163.06% to -$3.8 million in 2024, then soared by 94.13% to -$226000.0 in 2025.
- The last three Non Operating Income figures came in at -$226000.0 (Q4 2025), -$2.3 million (Q3 2025), and $528000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | 236,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236,000.00 |
| Dec 31, 2025 | -226,000.00 |
| Sep 30, 2025 | -2.34 Mn |
| Jun 30, 2025 | 528,000.00 |
| Mar 31, 2025 | 9.76 Mn |
| Dec 31, 2024 | -3.85 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | 19.75 Mn |
| Mar 31, 2024 | -14.46 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 24.94 Mn |
| Jun 30, 2023 | -29.89 Mn |
| Mar 31, 2023 | 5.29 Mn |
| Dec 31, 2022 | -3.51 Mn |
| Sep 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | -638,000.00 |
| Mar 31, 2022 | -674,000.00 |
| Dec 31, 2021 | -1.15 Mn |
| Sep 30, 2021 | -1.05 Mn |
| Jun 30, 2021 | -635,000.00 |